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Introduction
Alternative splicing (AS) is a key molecular mechanism in 
regulating gene expression and proteomic diversity. Recently, 
it has been shown that 95% of human genes undergo at least 
one AS event (Pan et al., 2008; Wang et al., 2008). Thus, AS 
is expected to play crucial roles in important biological events 
such as development, cell differentiation, organogenesis, and 
the response to environmental cues. Inclusion or exclusion of 
exons and alternative choices of 5 or 3 splice sites can give rise 
to different mRNAs from a single gene, which will be then 
translated into proteins with distinct functional activity or cel-
lular localization. In addition, AS can affect the RNA stability by 
inclusion of premature translation termination codons (PTCs)   
that activate the nonsense-mediated mRNA decay (NMD) path-
way (Isken and Maquat, 2008). In mammals, a termination codon 
is recognized as premature when located >50–55 nt upstream 
of the exon–exon junction marked by the exon junction com-
plex (EJC). EJCs downstream of PTCs are no longer removed 
during the “pioneer” round of translation, and recruit essential   
NMD factors, including Upf1/Rent1, that in turn promote   
mRNA degradation (Isken and Maquat, 2008). Initially, NMD   
was considered only a mechanism for disposing of aberrant mRNAs 
arising from nonsense codon–containing alleles. It is now evi-
dent that NMD is involved in quantitative posttranscriptional   
regulation of gene expression through specific AS events (AS-
activated NMD [AS-NMD], also termed regulated unproductive   
E
pithelial-to-mesenchymal  transition  (EMT)  and  its 
reversal (MET) are crucial cell plasticity programs 
that act during development and tumor metastasis. 
We have previously shown that the splicing factor and 
proto-oncogene  SF2/ASF  impacts  EMT/MET  through 
production of a constitutively active splice variant of the 
Ron proto-oncogene. Using an in vitro model, we now 
show that SF2/ASF is also regulated during EMT/MET by 
alternative splicing associated with the nonsense-mediated 
mRNA decay pathway (AS-NMD). Overexpression and 
small interfering RNA experiments implicate the splicing 
regulator Sam68 in AS-NMD of SF2/ASF transcripts and 
in  the  choice  between  EMT/MET  programs.  Moreover, 
Sam68 modulation of SF2/ASF splicing appears to be 
controlled by epithelial cell–derived soluble factors that 
act through the ERK1/2 signaling pathway to regulate 
Sam68 phosphorylation. Collectively, our results reveal   
a hierarchy of splicing factors that integrate splicing 
decisions into EMT/MET programs in response to extra-
cellular stimuli.
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kinase receptor for the macrophage-stimulating protein involved in 
control of cell scattering and motility (Trusolino and Comoglio,   
2002). SF2/ASF overexpression promotes skipping of Ron  
exon 11 and results in the production of Ron, a constitutively 
active isoform that confers an invasive phenotype to the cells 
(Ghigna et al., 2005). In this paper, we have exploited an in vitro 
model to further investigate the impact of AS programs on EMT. 
EMT can be recapitulated in vitro by growing colon adeno-
carcinoma cells at different densities: at low density, sparse cells 
mimic the situation occurring at the invasive front of the tumor 
and display a mesenchymal-like phenotype, whereas at high 
density, the same cells switch to an epithelial-like phenotype 
(Brabletz et al., 2001). We have found that the level of splicing   
factor SF2/ASF is controlled during in vitro EMT through 
AS-NMD.  This  event  is  regulated  by  diffusible  factors  ex-
pressed by epithelial cells through the ERK1/2 pathway and the 
Sam68 splicing regulator.
Results
AS of the Ron gene and expression level of 
SF2/ASF are regulated during in vitro EMT
Morphological and molecular hallmarks of EMT can be recapit-
ulated in vitro by growing colon adenocarcinoma SW480 cells 
at different densities: high-density (H) cells are similar to the 
central part of the tumor and display an epithelial-like pheno-
type, whereas low-density (L) cells resemble the invasive front 
of the tumor and have a mesenchymal-like phenotype (Brabletz 
et al., 2001). As shown in Fig. 1 A, L cells are poorly stained by 
an antibody against the epithelial marker E-cadherin and display 
nuclear accumulation of -catenin. Accordingly, expression 
of the E-cadherin gene is drastically higher in H cells than in 
L cells (Fig. 1 B). On the contrary, expression of vimentin and 
Slug genes, two typical markers of mesenchymal cells, increases 
during EMT and is higher in L cells (Fig. 1 B). We decided to 
study the splicing profile of Ron transcripts in this in vitro model 
of EMT. As shown in Fig. 1 C, cell density affects the splic-
ing profile of Ron exon 11, and the Ron mRNA is the prevail-
ing splicing isoform in sparse mesenchymal-like L cells, which 
is consistent with the ability of this splicing isoform to induce 
EMT. We have previously shown that the production of the Ron 
isoform correlates with the level of the splicing factor SF2/ASF 
(Ghigna et al., 2005). In agreement with this, the switch in the 
splicing profile of the Ron gene transcripts driven by cell density 
is paralleled by a higher level (4.5-fold) of SF2/ASF in L cells 
compared with that in H cells (Fig. 1 C).
Expression of SF2/ASF during EMT  
is regulated through AS-NMD
Recently, it has been found that AS-NMD regulates the expres-
sion of all SR splicing factors and several other RNA-binding 
proteins (Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 
2008). In particular, the 3 UTR of the SF2/ASF gene con-
tains an intron (3 UTR-intron) that is normally retained in the   
mature transcript (full-length [FL] transcript). Splicing of this 
intron produces an RNA molecule (NMD+ transcript) in which 
the natural stop codon is recognized as a PTC and the mRNA is 
splicing  and  translation;  Hillman  et  al.,  2004).  Recently,   
AS-NMD has been shown to regulate expression of specific 
gene families. Alternative “poison” exons containing premature 
in-frame stop codons, or introns in the 3 untranslated region 
(UTR), are particularly frequent in mammalian genes for splicing 
regulators, such as SR factors and heterogeneous nuclear RNP 
(hnRNP) proteins (Lareau et al., 2007; Ni et al., 2007) and for 
many core spliceosomal proteins (Saltzman et al., 2008). Most 
of these proteins can regulate their own mRNA level by modu-
lating AS-NMD in a feedback mechanism designed to maintain 
the protein homeostatic level (Saltzman et al., 2008). Interest-
ingly, in several genes for SR factors and hnRNPs, AS-NMD 
cassettes overlap highly conserved or ultraconserved elements 
(UCEs; Lareau et al., 2007; Ni et al., 2007) longer than 200 bp, 
with 100% identity among rat, mouse, and human genomes. 
However, the role of UCEs in AS-NMD and their contribution 
to diseases, including cancer, is still hypothetical.
Epithelial-to-mesenchymal  transition  (EMT)  is  an  im-
portant cell reorganization event that is crucially connected 
to developmental programs and occurs several times during   
embryogenesis in vertebrates. In adults, EMT is confined to a few 
physiological processes such as tissue regeneration and wound 
healing (Thiery and Sleeman, 2006). Notably, this program 
occurs during the progression of epithelial tumors and confers 
migratory and invasive properties to cancer cells (Thiery and 
Sleeman, 2006; Polyak and Weinberg, 2009). EMT describes 
a complex series of events during which epithelial cells lose 
many of their distinguishing features to acquire typical mes-
enchymal traits. Epithelial cells are rich in adherens junctions 
that are required for the formation of continuous cell layers. 
During EMT, epithelial cells acquire fibroblast-like morphology 
with a rearrangement of cytoskeletal architecture, reduced 
intercellular adhesion, and increased ability to invade nearby 
body districts (Thiery and Sleeman, 2006; Polyak and Weinberg, 
2009). A variety of oncogenic pathways, activated by peptide 
growth  factors,  Src,  Ras,  ETS,  integrin, Wnt/-catenin,  and 
Notch signaling, induce EMT (Thiery, 2003). A crucial event 
during EMT is the down-regulation of E-cadherin, a component   
of adherens junctions, which acts as a de facto tumor suppres-
sor, inhibiting invasion and metastasis, and is frequently re-
pressed or degraded during transformation. Down-regulation of   
E-cadherin is accompanied by increased expression of N-cadherin 
and vimentin by nuclear accumulation of -catenin, and in-
creased production of transcription factors, such as Snail and 
Slug, that inhibit E-cadherin production (Polyak and Weinberg, 
2009). Phenotypic markers of EMT include an increased capac-
ity of cell migration and three-dimensional invasion, as well as 
resistance to anoikis/apoptosis. Intriguingly, EMT is a transient 
process that occurs in a subset of cells at the invasive front of 
the metastasizing primary carcinomas and is reversed during 
the establishment of metastasis (Brabletz et al., 2001; Thiery 
and Sleeman, 2006). These cell morphology changes appear 
to be driven by several signals in the tumor microenvironment 
(Polyak and Weinberg, 2009). We have previously shown that 
EMT may be triggered by splicing factor and proto-oncogene 
SF2/ASF through the AS of the Ron proto-oncogene (Ghigna   
et al., 2005; Karni et al., 2007), which encodes the tyrosine 89 Sam68 controls EMT and AS-NMD of SF2/ASF oncogene • Valacca et al.
To rule out that this result could be due to pleiotropic effects 
of CHX rather than stabilization of NMD+ transcripts, we specifi-
cally targeted the NMD pathway by siRNA-mediated knockdown 
of the key NMD player Upf1 (Isken and Maquat, 2008). Simi-
larly to CHX, down-regulation of Upf1 changes the ratio between 
the two splicing products (Fig. 2 C) in L cells and augments the 
level of the NMD+ form in both L and H cells (Fig. 2 D). Consis-
tent with this, down-regulation of Upf1 in H cells also increases 
the SF2/ASF protein level. Altogether, these results support the 
conclusion that AS-NMD plays a role in controlling the level of 
splicing factor SF2/ASF during in vitro EMT. Notably, this event 
is not limited to our in vitro cell system, and FL and NMD+ SF2/
ASF splicing isoforms occur in normal human tissues as well 
(Fig. S2 A). The FL/NMD+ ratio varies in different tissues, which 
suggests that AS-NMD of SF2/ASF transcripts could play a physi-
ological role in maintaining the homeostatic SF2/ASF level in dif-
ferent district of the organism. In this regard, it is worth noticing 
that the FL/NMD+ ratio is altered in a fraction of colon tumor 
specimens compared with normal control tissues (Fig. S2 B). 
An intriguing possibility, which deserves further investigation, is 
that this deregulation may have a role in the higher level of the 
oncogenic SF2/ASF protein described by Karni et al. (2007).
degraded by the NMD pathway (Fig. 1 D; Lareau et al., 2007). 
We asked whether this mechanism could be responsible for 
the lower level of SF2/ASF in H cells. RT-PCR analysis shows 
that splicing of the 3 UTR-intron occurs in SW480 cells and 
is regulated during EMT: L cells express mainly the FL iso-
form, whereas the NMD+ transcript is predominant in H cells 
(Fig. 1 E). As predicted by the AS-NMD model, this splicing 
switch is accompanied by a lower level (about threefold as esti-
mated by real-time quantitative RT-PCR [qRT-PCR] of SF2/ASF 
mRNAs in H cells (Fig. 1 F). NMD occurs during the pioneer 
round of translation, and NMD substrates are stabilized by the 
translation inhibitor cycloheximide (CHX; Isken and Maquat, 
2008). To verify the involvement of the NMD pathway in the   
regulation of SF2/ASF mRNA levels, we treated SW480 cells 
with CHX. As shown in Fig. 2 B (left), CHX changes the ratio 
between the two splicing products in L cells and specifically in-
creases the level of NMD+ transcripts. A similar effect of CHX 
is also detectable in H cells using the primer set D-B (Fig. 2 A), 
which specifically amplifies the NMD+ splicing product (Fig. 2 B, 
middle). Accordingly, qRT-PCR (Fig. 2 B, right) demonstrates 
that the total level of SF2/ASF transcripts in H cells increases 
when cells are treated with CHX.
Figure  1.  Splicing  profile  of  Ron  and  SF2/ASF  transcripts   
during in vitro EMT. (A) H (High) and L (Low) cells were analyzed 
in immunofluorescence for the expression of E-cadherin and the 
distribution of -catenin (bottom two rows; magnification 60×; 
bar, 10 µm); cell morphologies were examined under a phase 
contrast microscope (top row; magnification 10×; bar, 30 µm). 
(B) RT-PCR analysis of indicated EMT markers in SW480 cells 
at different densities. The histogram shows the ratio between 
the mRNA levels quantified in H and L cells by qRT-PCR. Error   
bars indicate mean ± SD. (C) RT-PCR analysis of Ron splicing 
and  Western  blotting  of  SF2/ASF  and  -tubulin  proteins  in 
SW480 cells at different densities. (D) Schematic representa-
tion of AS in the 3 UTR of SF2/ASF transcripts. Intron retention 
generates the stable FL transcript of SF2/ASF, whereas splicing 
leads to the assembly of an EJC downstream of the natural stop 
codon (NMD+ transcript). The position of primers ASF-A and 
-B is indicated. (E) Splicing profile of SF2/ASF transcripts in 
H and L SW480 cells. Total RNAs were analyzed by RT-PCR 
with primers ASF-A and -B flanking the 3 UTR-intron (see D).   
(F) RT-PCR analysis of RNAs with primers annealing to constitutive   
SF2/ASF  exons  (exons  2  and  3)  and  with  primers  for  the 
GAPDH gene. The histogram shows the qRT-PCR analysis, with 
primers ASF-tot-for and -rev, of the total SF2/ASF transcripts 
in SW480 cells at different densities. Error bars indicate SD 
calculated from three independent experiments.JCB • VOLUME 191 • NUMBER 1 • 2010   90
H cells, plated on top of the insert, is sufficient to increase the 
level of the NMD+ transcripts in L cells in the lower chamber 
(Fig. 3 A), whereas co-culture with L cells had no effect on 
H cells (not depicted). It is plausible that this unidirectionality 
reflects the stoichiometry of factors expressed by L and H cells 
in co-culture experiments.
To further investigate this aspect, we grew H cells in the 
presence of conditioned medium from L cells and vice versa. 
In accord with the co-culture experiment, conditioned medium 
from L cells did not change the AS profile in the 3 UTR of   
SF2/ASF mRNA (unpublished data), whereas conditioned medium 
from H cells (High-CM) shifts the splicing profile of SF2/ASF 
transcripts in L cells toward the production of the NMD+ form 
(Fig. 3 B), with a concomitant reduction of SF2/ASF mRNA 
(twofold) and protein (2.3-fold) levels and, as a consequence, 
of Ron transcripts (Fig. 3 C). More importantly, High-CM 
affected molecular markers that distinguish mesenchymal from 
Soluble factors secreted by epithelial cells 
control AS-NMD of SF2/ASF transcripts 
and induce the mesenchymal-to-epithelial 
transition (MET)
Growth factors control the interaction and communication be-
tween epithelial and mesenchymal cells during development 
(Shannon and Hyatt, 2004). Recently, it has been reported that 
soluble factors secreted by tumor mammary mesenchymal 
cells regulate the AS profile of the fibronectin gene in nor-
mal mammary epithelial cells (Blaustein et al., 2004). Thus, 
we asked whether factors secreted by mesenchymal L cells or 
epithelial H cells could control splicing in the 3 UTR of the 
SF2/ASF transcripts.
To reproduce the epithelial–mesenchymal interaction and 
assess its influence on AS, we performed co-culture experiments 
with tissue culture inserts that allow the interchange of soluble 
factors without cell–cell contacts. Interestingly, co-culture with 
Figure 2.  The NMD+ transcript of SF2/ASF is degraded by the NMD pathway. (A) Scheme of the SF2/ASF primers used in RT-PCR analysis. ASF-D is 
specific for the NMD+ transcript. (B) L cells (Low cells) were treated for 6 h with CHX, and RNAs were then analyzed by RT-PCR with primers ASF-A   
and -B (left). Control, untreated cells. H cells (High cells), treated with CHX for 6 h, were analyzed by RT-PCR with ASF-D and -B primers and with primers 
for the GAPDH gene (right). The histogram shows the relative quantification of the total SF2/ASF transcripts by qRT-PCR, performed as in Fig. 1 F, in H cells. 
Error bars indicate SD calculated from three independent experiments. (C) L cells were transfected with Upf1 siRNA or with GL2-Luciferase siRNA (GL2-Luc) 
and then analyzed in a Western blot with anti-Upf1 and anti–-tubulin antibodies, and in RT-PCR with primers ASF-A and -B. (D) H cells, treated with the 
indicated siRNA oligos, were analyzed in RT-PCR with primers specific for the NMD+ transcript of SF2/ASF as in B or for GAPDH gene transcripts (E), and 
by Western blotting with anti–SF2/ASF and –-tubulin antibodies.91 Sam68 controls EMT and AS-NMD of SF2/ASF oncogene • Valacca et al.
metastasis (Thiery and Sleeman, 2006). However, the mecha-
nisms by which ERK1/2 controls motile and invasive capacities 
of epithelial cells are not well understood. We decided to inves-
tigate the involvement of the ERK1/2 pathway in the regulation 
of SF2/ASF splicing during EMT. As shown in Fig. 4 A, phos-
phorylation of ERK1/2 kinase is higher in L cells compared 
with H cells, whereas the phosphorylation status of the stress   
kinase p38, which identifies another pathway activated by 
growth factors, is not affected by cell density. Moreover, treat-
ment of L cells with conditioned medium from H cells, as in 
Fig. 3, is accompanied by a decreased ERK1/2 phosphorylation 
(Fig. 4 B). Collectively these observations suggest an involve-
ment of ERK1/2 in the regulation of AS-NMD of SF2/ASF tran-
scripts. To directly verify this possibility, we specifically inhibited 
the ERK1/2 activity in L cells with the small molecule U0126 
(Fig. 4 C). As shown in Fig. 4 D, U0126 changes the splicing pro-
file of SF2/ASF mRNA in L cells and favors the production of 
the NMD+ isoform typical of epithelial H cells. As a result, the 
SF2/ASF protein level decreases and the splicing profile of Ron 
transcripts switches to the epithelial program with reduction of 
the Ron splicing product (Fig. 4 D). Importantly, inhibition of 
ERK1/2 in L cells activates the epithelial expression program 
characterized by increased expression of E-cadherin and down-
regulation of vimentin mRNAs (Fig. 4 D). Altogether, our results 
implicate the ERK1/2 signaling cascade in the choice between 
the epithelial and mesenchymal status of SW480 cells. Inhibi-
tion of this pathway by soluble factors expressed by epithelial 
H cells or with the ERK1/2 inhibitor U0126 uncouples the   
occurrence of MET from cell density, and regulates AS-NMD 
of SF2/ASF transcripts and Ron mRNA production.
Sam68 interacts with the 3 UTR of the 
SF2/ASF transcript
To understand the molecular mechanism regulating AS-NMD 
of SF2/ASF transcripts, we analyzed the SF2/ASF 3 UTR se-
quence. This region contains two UCEs that overlap the exon 
junctions (Fig. 5 A). Two putative binding sites (AAAAUU) for 
the splicing regulator Sam68 (Matter et al., 2002) are located 
near the UCEs (A and B in Fig. 5 A). Sam68, the 68-kD Src-
associated protein in mitosis, is a member of the STAR (signal 
transduction activator of RNA) family of RNA-binding pro-
teins proposed to link signaling cascades to RNA metabolism 
(Lukong and Richard, 2003). Notably, Sam68 is a substrate of 
ERK1/2 kinase and controls splicing of exon v5 of the CD44 
gene after Ras activation (Matter et al., 2002). In agreement with 
the activation of the ERK1/2 pathway, we found that Sam68 is 
hyperphosphorylated in L cells (Fig. 5 B), and its phosphoryla-
tion level is reduced upon treatment with the extracellular 
signal–regulated kinase (ERK) inhibitor U0126 (Fig. 5 C).
As a first step to understanding whether Sam68 may   
control AS in the 3 UTR of SF2/ASF transcripts, we performed 
in vitro pull-down assays using riboprobes spanning the Sam68 
putative binding sites (Fig. 5 A). As shown in Fig. 5 D, Sam68 
binds to both riboprobes, and binding is abrogated by mutating 
the Sam68 recognition sequence to AACACU. To determine if 
Sam68 binds to the SF2/ASF 3 UTR in vivo, we performed 
RNA immunoprecipitation with an antibody that recognizes both 
epithelial cells, leading to the increased expression of E-cadherin 
and the concomitant reduction in the Slug and vimentin mRNA 
levels (Fig. 3 D). Moreover, a partial cytoplasmic accumulation 
of -catenin was visible (Fig. 3 D, right). Collectively, these ob-
servations suggest that soluble factors released in the medium 
by high-density epithelial-like SW480 cells act dominantly in 
activating MET in L cells.
Soluble factors act through the ERK1/2 
pathway to regulate AS-NMD of SF2/ASF 
transcripts and production of the  
Ron mRNA
Several secreted growth factors exert their action by activating 
the ERK1/2 pathway (Dhillon et al., 2007), which stimulates 
most forms of epithelial invasive motility that occur during 
cell scattering, wound healing, EMT, malignant invasion, and 
Figure 3.  Factors secreted by H cells control the AS of SF2/ASF transcripts 
and EMT markers in L cells. (A) Analysis of AS in SF2/ASF 3 UTR in a 
co-culture experiment. L (Low) or H (High) cells (as indicated above the   
image of the gel) were grown on a porous filter placed inside a tissue cul-
ture well containing L cells. After 24 h, L cells in the bottom chamber were 
analyzed by RT-PCR as in Fig. 1 E. (B) L cells were plated in 3% serum into 
35-mm tissue culture wells, and after 24 h, they were left untreated () or 
treated with conditioned medium from H cells (High-CM) for an additional 
24 h. Total RNAs were analyzed by RT-PCR as in Fig. 1 E. The histogram 
shows the analysis of the total SF2/ASF transcripts by qRT-PCR in L cells 
treated or not treated with High-CM. Error bars indicate SD calculated from 
three independent experiments. (C) Total RNAs from L cells treated or not 
treated with High-CM were analyzed in a Western blot with SF2/ASF and 
-tubulin antibodies and in RT-PCR for Ron splicing. (D) Total RNAs were 
also analyzed by RT-PCR with primers for the indicated EMT markers and 
GAPDH gene transcripts. The same cells were stained with an antibody 
specific to -catenin and counterstained with DAPI (magnification 63×). 
Arrows indicate the cytoplasmic accumulation of -catenin. Bar, 10 µm.JCB • VOLUME 191 • NUMBER 1 • 2010   92
nucleotide was substituted in the Sam68 consensus sequence 
(AAAACU). Although less marked than previous mutants,   
Mut A1 and Mut B1 also show a shift toward the production 
of t-NMD+ RNAs in L cells. Remarkably, the mutation of both 
sites (Mut A1+B1) gives the maximal effect on splicing (Fig. 6 B)   
and reduces the interaction with Sam68 in a pull-down assay 
(Fig. 6 B). We then tested all these minigenes in H cells. Simi-
larly to the endogenous SF2/ASF RNA, WT minigene transcripts 
mainly undergo 3 UTR-intron removal with the production of 
t-NMD+ molecules (Fig. 6 C). As expected from the fact that 
Sam68 sites are affected, the same preferential expression of 
t-NMD+ RNAs is observed with all mutants, even though some 
differences are visible (Fig. S4 and the histogram in Fig. 6 C).
To directly assess the effect of Sam68 on the splicing of the 
3 UTR-intron, the various Mut constructs were cotransfected 
in H cells with plasmids directing the expression of Sam68 or 
of the Sam68 V229F mutant, which is impaired in RNA binding 
(Paronetto et al., 2007). As shown in Fig. 6 C, overexpression of 
Sam68 inhibits splicing of the 3 UTR-intron, with the produc-
tion of t-FL molecules, and gives rise to a profile similar to that 
observed in L-cells. This result clearly involves Sam68 in the 
regulatory circuit that controls splicing decision in the 3 UTR 
region of SF2/ASF transcripts. However, Sam68 also promotes   
intron retention, although to a lower extent, in transcripts encoded 
by mutated minigenes. It is plausible that this behavior actually 
the phosphorylated and unphosphorylated forms of Sam68. As 
shown in Fig. 5 E, Sam68 binds in vivo to the endogenous   
SF2/ASF transcript but not to GAPDH mRNA.
Sam68 controls AS-NMD of SF2/ASF 
transcripts and mesenchymal-to-epithelial 
cell transition
Based on the result in the previous paragraph, we hypoth-
esized a role of Sam68 in controlling AS-NMD of SF2/ASF 
transcripts. To verify this possibility, we analyzed the in vivo 
splicing of minigene transcripts containing either the wild-type 
(WT) SF2/ASF 3 UTR or mutated versions in which one or 
both Sam68 binding sites were substituted with AACACU (Mut A,   
Mut B, and Mut A+B). Similarly to endogenous SF2/ASF 
transcripts, RNAs encoded by the WT minigene mainly show   
3 UTR-intron retention in L-cells (t-FL in Fig. 6 B). Mutation 
of one Sam68 binding site reduces intron retention (t-NMD+); 
this is more evident in the case of Mut A, which points to a role   
of these sequence elements in the splicing decision. Unexpect-
edly, however, when both sites are contemporarily mutated (Mut   
A+B), the effect is lower than that observed with Mut A (Fig. S3 
and the histogram in Fig. 6 B), as if Mut A+B is responding   
to some other splicing regulatory mechanism. In an attempt 
to circumvent this problem, we generated another set of mutants 
(Mut A1, Mut B1, and Mut A1+B1 in Fig. 6 A) in which a single 
Figure 4.  Factors secreted by H cells act through the ERK1/2 pathway. (A) Western blot with phospho-specific (p-) and pan-antibodies (tot) against ERK1/2 
and p38 kinases in SW480 cells grown at different densities. (B and C) Western blot analyses of the ERK1/2 phosphorylation status in L cells (Low) treated 
or untreated with High-CM (B), or treated with the specific ERK1/2 inhibitor U0126 (+) or with DMSO () (C) . (D) L cells treated with U0126 were also 
analyzed for the splicing profile of the 3 UTR-intron (RT-PCR with primers ASF-A and -B), the total level of SF2/ASF transcripts by qRT-PCR (histogram), the 
SF2/ASF and -tubulin protein levels, Ron splicing, and the mRNA expression levels of the indicated EMT markers and GAPDH gene. Error bars indicate 
SD calculated from three independent experiments.93 Sam68 controls EMT and AS-NMD of SF2/ASF oncogene • Valacca et al.
does not abrogate, the interaction with Sam68 in the pull-down 
assay (Fig. 6 B). The necessity of a direct protein–RNA inter-
action is also supported by the behavior of the V229F mutant 
reflects the interaction of Sam68 with sequence elements in the 
3 UTR-intron related to the consensus binding site. Consistent 
with this hypothesis, the mutation of both sites decreases, but 
Figure 5.  Sam68 binds to the 3 UTR-intron of SF2/ASF transcripts. (A) Schematic representation of the 3 UTR region of the SF2/ASF gene. The relative 
positions of UCEs and Sam68 binding sites A and B are indicated. Below is the reported the sequence of the 3 UTR region between the two UCEs (gray 
boxes). The sequence of the exons is indicated in uppercase, and the 3 UTR-intron is in lowercase. The two putative Sam68 binding sites (AAAAUU, called 
A and B) are shown with gray ovals. The 100-mer riboprobes spanning the two binding sites are in bold. (B and C) Analysis of the phosphorylation status 
of Sam68 in H (High) and L (Low) cells (B) or in L cells untreated or treated with the specific ERK inhibitor U0126 (C). Sam68 was immunoprecipitated 
with anti-Sam68 or IgG antibodies and then analyzed in a Western blot with anti–phospho-threonine-proline (-pTP) and Sam68 antibodies. The panel on 
the right shows the Western blot analysis of L cell extracts, untreated or treated with U0126, with anti-Sam68 and anti-pTP antibodies. (D) An in vitro pull-
down assay with HeLa nuclear extracts and with 100-mer RNA probes (see A) containing the WT (A or B) Sam68 binding sites or the mutated sequences 
Mut A or Mut B. All probes contain at their 3 end the binding sequence for the splicing factor TDP-43 as an internal control of pull-down efficiency.   
(E) Immunoprecipitation of the SF2/ASF 3 UTR from in vivo cross-linked L cells using anti-Sam68 or IgG antibodies. The immunoprecipitated RNA was 
analyzed by RT-PCR with primers annealing to the 3 UTR-intron (ASFbsB-for and ASFbsB-rev primers) and with primers for the GAPDH gene (left, top). 
Western blot analysis of the immunoprecipitated materials with anti-Sam68 and IgG antibodies (left, bottom) is shown. The immunoprecipitated RNAs were 
also analyzed by q-RT-PCR using ASFbsB-for and ASFbsB-rev primers and primers for GAPDH (histogram on the right). Error bars indicate SD calculated 
from three independent experiments.JCB • VOLUME 191 • NUMBER 1 • 2010   94
phosphorylation of this factor by ERK1/2 may be critically 
linked to the switch in the splicing profile of SF2/ASF tran-
scripts. To verify this hypothesis, we cotransfected L cells with   
the WT SF2/ASF 3 UTR minigene and with plasmids di-
recting  the  expression  of  either  Sam68  WT  or  Sam68  in 
which the eight ERK phosphorylation sites were mutated to 
alanine (Mut 1; Matter et al., 2002). As shown in Fig. 6 D, 
mutation of the ERK1/2 phosphorylation sites reduced the 
(Fig. 6 C), which displays a strongly reduced ability to stimu-
late 3 UTR-intron retention. The residual activity may reflect 
the interaction with some other, still unidentified, proteins that 
bind to the minigene transcript. This possibility has been recently 
advanced to explain the ability of the V229F mutant to stimulate 
splicing of the RTL4-T transcripts (Liu et al., 2009).
Because  the  level  of  Sam68  does  not  appreciably 
change during EMT (unpublished data), we asked whether 
Figure  6.  Sam68  triggers  retention  of  the  3  UTR-intron.  
(A) Comparison between WT and mutated A and B sites. 
Boxes  highlight  residues  that  are  changed  in  the  different   
mutants; underlined residues indicate a mutated nucleotide in 
a specific mutant. (B) L cells (Low cells) were transfected with a 
minigene containing the WT SF2/ASF 3 UTR or with deriva-
tives with one (Mut A, Mut B, Mut A1, and Mut B1) or both 
Sam68 binding sites (Mut A+B and Mut A1+B1) mutated. 
t-FL and t-NMD+, minigene transcripts generated by retention 
and splicing of the 3 UTR-intron, respectively. The histogram 
on the right shows the ratio between t-FL and t-NMD+ splic-
ing products calculated from three independent experiments. 
(B, bottom right) Western blot analysis with anti-Sam68 and 
anti-TDP43  antibodies  of  a  pull-down  experiment,  as  in   
Fig. 5 D, performed with a 965-mer riboprobe spanning the 
3 UTR-intron from 50 nt upstream of the Sam68-binding site 
A to 50 nt downstream of the Sam68 binding site B, in either 
WT or mutated. (C) WT, Mut A1, Mut B1, and Mut A1+B1   
minigenes were cotransfected into H cells (High cells) along 
with a plasmid encoding the GFP-tagged WT Sam68, the 
GFP-tagged  V229F  mutant,  or  the  empty  vector  (left).  The 
same experiment was performed with Mut A, Mut B, and Mut 
A+B minigenes (Fig. S4). The histogram on the right shows 
the t-FL/t-NMD+ ratio calculated in three independent experi-
ments. Expression of tagged Sam68 proteins was verified by   
Western blotting with anti-GFP and anti-Sam68 antibodies (left). 
(D) A minigene containing the WT sequence of the SF2/ASF 
3 UTR region was cotransfected into L cells along with a plas-
mid encoding the myc-tagged WT Sam68, the myc-tag Mut 1 
(Matter et al., 2002), or the empty vector. The splicing profile 
of minigene transcripts was analyzed in RT-PCR, and the ratio 
between the two splicing products is shown in the histogram 
on the right. The expression of the tagged proteins was veri-
fied by Western blotting with antibodies against Sam68 and 
against the myc tag. Error bars indicate SD calculated from 
three independent experiments.95 Sam68 controls EMT and AS-NMD of SF2/ASF oncogene • Valacca et al.
is one of the mechanisms that control the expression of a large 
number of pre-mRNA processing factors, many of which di-
rectly modulate AS-NMD of their own transcript, thus maintain-
ing, through a sort of feedback mechanism, their homeostatic 
level (Isken and Maquat, 2008). Splicing regulators may also 
modulate AS-NMD in transcripts of other RNA-binding pro-
teins. This is the case of two pairs of closely related hnRNP   
proteins—polypyrimidine  tract-binding  protein  (PTB)/neural 
PTB (nPTB) and hnRNP L/hnRNP LL—that control their rela-
tive  abundance  during  cell  differentiation  through AS-NMD 
(Spellman et al., 2007; Rossbach et al., 2009). We have identi-
fied another example of regulated AS-NMD in which the level 
and/or  phosphorylation  status  of  Sam68  affects  the  level  of 
SF2/ASF by regulating unproductive splicing in the 3 UTR   
of  SF2/ASF  transcripts.  As  observed  for  PTB/nPTB  and 
ability of Sam68 to modulate the splicing profile of WT mini-
gene transcripts.
Altogether, these results suggest that differential splicing 
of minigene transcripts during EMT is controlled by the inter-
action of Sam68 with the two binding sites in the 3 UTR-intron 
and is modulated by protein phosphorylation.
To investigate the effect of Sam68 on the splicing profile 
of the endogenous SF2/ASF transcripts, we generated a clone 
of SW480 cells stably overexpressing Myc-tagged Sam68   
(cl. Sam68). As shown in Fig. 7 A, a twofold increase in Sam68 
expression is sufficient to augment the ratio of FL to NMD+ 
mRNAs, leading to a higher level of SF2/ASF total mRNA. 
This is accompanied by an increased level of SF2/ASF protein 
and by a switch in the splicing profile of Ron gene transcripts 
(Fig. 7 B). Strikingly, cl. Sam68 cells are unable to undergo 
MET. Indeed they do not acquire the typical epithelial morphol-
ogy of SW480 cells and display elongated and spindle-shaped 
morphology typical of mesenchymal cells even at high density. 
Moreover, they fail to up-regulate E-cadherin and show consti-
tutive expression of Slug and vimentin (Fig. 7 C). To confirm the 
involvement of Sam68 in AS-NMD of SF2/ASF transcripts, we 
used siRNA to down-regulate endogenous Sam68 expression 
in L cells, which display high levels of FL mRNA. As shown 
in Fig. 7 D, down-regulation of Sam68 results in a shift of the 
splicing profile toward the NMD+ isoform and in an overall 
reduction  of  SF2/ASF  transcription  levels.  Accordingly,  we 
observed a switch in the splicing pattern of Ron transcripts, in-
creased expression of E-cadherin, and reduced transcription of 
Slug (Fig. 7 E). On the basis of these observations, we suggest 
that the level and/or activity of the splicing regulator Sam68 
contributes to determine the choice between the epithelial and 
mesenchymal status. Notably, a higher level of Sam68 mRNA 
is observed in a fraction of colon tumors (Fig. S2).
Discussion
In this manuscript, we have investigated the relevance of AS to 
the EMT or its reversal MET. Both EMT and MET are reversible 
processes that result from the activation of gene expression pro-
grams crucial for normal development. However, they are patho-
logically exploited during the progression of well-differentiated 
epithelial tumors (Polyak and Weinberg, 2009). EMT-like cell 
dedifferentiation takes place at the invasive front of carcino-
mas, favoring detachment, migration, and dissemination of can-
cer cells. Redifferentiation with regain of epithelial features in 
a MET-like process occurs at the final metastatic site (Thiery 
and Sleeman, 2006). Our analysis indicates that cell growth 
conditions and external cues act through the ERK1/2 signaling 
pathway to modulate the activity and expression levels of two 
splicing regulators, Sam68 and SF2/ASF, critically involved in 
EMT/MET programs in SW480 cells.
AS, NMD pathway, and expression of the 
SF2/ASF proto-oncogene
A recent work on splicing factor SF2/ASF has shown that mul-
tiple posttranscriptional and translational mechanisms operate 
to fine-tune the level of this protein (Sun et al., 2010). AS-NMD 
Figure 7.  Sam68 controls AS in the SF2/ASF 3 UTR and the activation 
of the MET program. (A) SW480 cells were stably transfected with myc-
tagged Sam68 (cl. Sam68) or with the empty vector (vector). Western blot 
analysis of extracts from cl. Sam68 and “vector” H cells (High cells) with 
anti-Sam68 antibody. H cells were also analyzed to determine the splicing 
profile of the 3 UTR-intron (RT-PCR with primers ASF-A and B) and the level 
of the total SF2/ASF transcripts by qRT-PCR (histogram). (B) The protein 
levels of SF2/ASF and -tubulin and the splicing profile of the Ron gene 
transcripts. (C) The morphology of cl. Sam68 and “vector” cells grown at 
high density was examined under a phase-contrast microscope (magnifica-
tion 60×), and the mRNA expression levels of the indicated EMT markers 
and GAPDH gene were determined by RT-PCR. Bar, 10 µm. (D) L cells 
(Low cells) were transfected with Sam68 or with GL2-Luciferase siRNAs. 
Cells were analyzed by Western blotting with anti-Sam68 and -tubulin 
antibodies and by RT-PCR to reveal the splicing profile of the 3 UTR region 
of the endogenous SF2/ASF transcripts (primers ASF-A and -B). The histo-
gram shows the relative quantification of the total SF2/ASF transcripts by 
qRT-PCR. (E) L cells knocked down for Sam68 were analyzed in RT-PCR to 
determine the Ron splicing. Note that images of Ron splicing derive from 
different part of the same agarose gel. The same cells were also analyzed 
for the expression level of the indicated EMT markers. Error bars indicate 
SD calculated from three independent experiments.JCB • VOLUME 191 • NUMBER 1 • 2010   96
proteins (Gazel et al., 2008). Our data suggest that, at least for 
SF2/ASF, the increment in mRNA levels may reflect inhibition 
of unproductive splicing, raising the possibility that posttran-
scriptional regulation of RNA stability by AS-NMD might ac-
count for part of these changes in mRNA levels. Altogether, our 
results therefore suggest that ERK1/2 may contribute to tumor 
metastasis by modulating AS events critically linked to EMT.
It is commonly accepted that tumor cells accumulate wide-
spread chromosomal changes and somatic mutations that pre-
dispose to EMT and metastasis. Although the highly aberrant 
genomes of tumor cells are consistent with this idea, our data 
support an alternative model in which a subset of the tumor   
metastasizes as a consequence of its unique responsiveness to 
diverse microenvironmental cues. An unresolved issue is whether 
diffusible factors in the tumor microenvironment are also in-
volved in MET induction. It has been suggested that, in the ab-
sence of signals that actively promote EMT, mesenchymal tumor 
cells could revert to the epithelial state once they reached the 
final metastatic location as a consequence of a transcriptional 
default mechanism (Polyak and Weinberg, 2009). Interestingly, 
our data indicate that, at least in the case of SW480 cells, factors 
secreted by epithelial cells act dominantly to activate MET. It is, 
therefore, plausible that cancer cells may undergo MET in re-
sponse to signals coming from surrounding epithelial cells.
Although MET is induced in mesenchymal-like SW480 
cells by factors present in the conditioned medium of epithelial-
like H-cells, we failed to observe the opposite phenomenon, i.e., 
induction of mesenchymal markers in epithelial-like H cells 
in response to factors expressed by mesenchymal-like L cells 
(unpublished data). This could be simply due to the fact that 
relevant growth factors expressed by L cells are too diluted to 
trigger EMT in H cells. An alternative explanation takes into 
account the fact that SW480 cells express a constitutively active 
Ras (K-RasV12) mutant that activates ERK1/2 (Dhillon et al., 
2007) and expression of mesenchymal markers. Indeed, phar-
macological inhibition of ERK1/2 activity in L cells induces 
MET. Interestingly, the transition of mesenchymal SW480 cells 
to an epithelial-like state (MET) is accompanied by inactivation 
of the ERK1/2 pathway (Fig. 4). Thus, in line with recent find-
ings (Gibbons et al., 2009) and despite having numerous somatic 
genetic mutations, SW480 cells retain a marked plasticity and 
may undergo reversible EMT. Different possible molecular mecha-
nisms by which H cells bypass constitutive K-RasV12 can be 
proposed, and their relevance will be investigated in the future. 
Interestingly, some of them involve the expression of specific 
microRNAs or AS events in kinases acting downstream of Ras.
The splicing regulator Sam68  
is a master controller of AS in response  
to ERK1/2 activation
Sam68 is a member of the STAR family of RNA-binding pro-
teins that links extracellular signals to RNA metabolism (Lukong 
and Richard, 2003). The molecular mechanism through which 
Sam68 regulates AS decisions in response to signaling cascades 
is poorly understood. Previously, it has been shown that phosphory-
lation of Sam68 by ERK1/2 stimulates inclusion of the CD44 
exon v5 (Matter et al., 2002), an exon frequently included 
hnRNPL/hnRNPLL pairs, regulation of the SF2/ASF protein 
level by Sam68 is involved in cell differentiation programs, 
namely the EMT–MET transitions. The identification of a regu-
lative circuit in which a splicing regulator, Sam68, controls the 
level of an unrelated one, SF2/ASF, opens a new layer of com-
plexity in splicing regulation. In particular, it unveils a hierarchy 
of actions between splicing factors in which Sam68 links the 
signaling pathway to downstream effectors such as SF2/ASF. 
Thus far, we know only one target of this circuit, i.e., the Ron 
proto-oncogene that, through AS, produces the Ron isoform 
able to trigger EMT. However, it is likely that other transcripts 
for proteins involved in the EMT program are also controlled.
We found that Sam68, an ERK1/2 target, binds to A/U-
rich motifs near the UCEs that flank the 3 UTR-intron. Inter-
estingly,  the  association  between  UCEs  and  Sam68  binding 
sites in the SF2/ASF gene is evolutionarily conserved (Fig. S1). 
In particular, the distance between binding site B (Fig. 5) and 
the downstream UCE is identical (117 bp) in the rat and human 
genes, and the B site is the only one conserved in mice (Fig. S1).   
This suggests a relevant function of this element in the AS of 
SF2/ASF transcripts that, as indicated by EST analysis, occurs 
in mice and rats as well.
Connection between the ERK1/2 signaling 
pathway and splicing control
The mechanisms used by oncogenes or tumor suppressors   
to regulate malignant transformation are becoming progressively 
better understood. Recently, the emphasis on crucial events during   
tumor progression is changing, as many molecular and epi-
genetic changes seem to cooperate in altering tumor cell behavior. 
Despite of its prevalence and importance (Ghigna et al., 2008), 
very little is known about the role of AS in tumorigenesis.
A remarkable finding of our analysis is that morphologi-
cal and molecular markers of mesenchymal cells and AS-NMD 
of SF2/ASF transcripts are controlled by soluble factors present   
in the epithelial cell–conditioned media. We have shown that 
these factors repress the activity of the extracellular signal– 
regulated  kinase  ERK1/2  and  Sam68  phosphorylation,  thus 
leading to a switch in the splicing profile of the SF2/ASF tran-
script. Interestingly, the role of the ERK1/2 pathway seems to be 
specific, as we did not detect alteration of the signaling path-
way identified by p38 kinase, another cascade regulated by extra-
cellular cues.
The ERK1/2 pathway mediates the response to growth 
signals and controls cell proliferation and survival, cell adhe-
sion, angiogenesis, and cancer metastasis (Fang and Richardson, 
2005). This signaling cascade includes several proto-oncogenes 
and is deregulated in approximately one third of all human can-
cers (Dhillon et al., 2007). Interestingly, ERK1/2 activation is 
associated to induction of EMT (Thiery and Sleeman, 2006). 
Among the hundreds of ERK1/2 substrates, very few direct   
effectors have been identified with respect to induction of EMT. 
Even though the molecular details remain poorly understood, 
it has been suggested that ERK1/2 operates through regulation 
of transcription (Fang and Richardson, 2005; Thiery and Sleeman, 
2006). Notably, during epidermal differentiation, ERK1/2 acti-
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cell monolayers were rinsed, and an insert, containing L or H cells cultured 
on top of the porous filter, was placed inside each well. Cells in the bottom 
well were analyzed after 24 h of co-culture.
Conditioned medium (CM) was obtained by plating H or L SW480 
cells into 35-mm tissue culture dishes in RPMI with 3% FBS. CM was col-
lected 24 h later and centrifuged to discard cell debris.
H cells were treated with 10 µg/ml cycloheximide (Sigma-Aldrich) 
for 6 h before analysis. L cells were treated with 40 µM U0126 (Sigma-
Aldrich)  and  analyzed  after  24  h.  As  a  control,  L  cells  were  treated   
with DMSO.
Normal human tissues and cancer specimens
RNAs prepared from pathologically confirmed primary nonfamilial colon   
adenocarcinomas  and  neighboring  normal  colon  tissues  have  been   
described  previously  (Ghigna  et  al.,  2005).  3  µg  of  total  RNA  from   
normal human tissues (Clontech) and from colon tumors was analyzed   
with RT-PCR.
Plasmids
To generate the plasmid containing the WT 3 UTR region of SF2/ASF 
transcripts, this sequence was PCR amplified with primers ASF-A and -B   
(Table S1) by using cDNA from L cells. The amplification band was then 
cloned into the EcoRV site of pcDNA3.1(+) (Invitrogen) and then sequenced. 
The mutated minigenes Mut A, Mut B, Mut A+B, Mut A1, Mut B1, and   
Mut A1+B1, all in pcDNA3.1(+), were generated by PCR-mediated muta-
genesis and sequenced. The GFP-tagged Sam68 expression plasmids were 
provided by D. Elliott (Institute of Human Genetics, Newcastle University, 
Centre for Life, Newcastle upon Tyne, England, UK), whereas Myc-tagged 
Sam68-mut1 was provided by H. Köning (Forschungszentrum Karlsruhe 
GmbH, Institut für Toxikologie und Genetik, Karlsruhe, Germany).
RT-PCR
3 µg of DNase-treated total RNA was retro-transcribed with d(T)18 and 
Superscript II RT (Invitrogen). An aliquot (1/20th) was then PCR amplified. 
For analysis of AS-NMD of SF2/ASF RNA, we used primers ASF-A or 
ASF-D in combination with ASF-B, whereas to detect total SF2/ASF tran-
scripts, we used ASF_cost_for and ASF_cost_rev (Table S1). Total RNA from 
SW480 cells, transfected with SF2/ASF 3 UTR minigenes, were RT-PCR 
analyzed with the primers ASF-A and BGHrev (Ghigna et al., 2005), the 
latter of which anneals to the vector sequence. Primers used to amplify Ron,   
E-cadherin, and GAPDH transcripts have been described previously (Ghigna 
et al., 2005). For other EMT markers, we used VimEX6 with VimEX6-7 and 
SlugEx2 with SlugEx2-3. All primers are listed in Table S1.
qRT-PCR
An aliquot (1/20th) of the RT reaction was used in a quantitative PCR 
with the QuantiTec SYBR Green PCR kit (QIAGEN). PCR was performed 
on LightCycler 480 (Roche). The level of GAPDH or HP0 transcripts was 
used  to  normalize  the  mRNA  levels  of  SF2/ASF  and  Sam68,  and  the 
EMT markers E-cadherin, Slug, and vimentin (primers listed in Table S2). 
The expression of each gene was measured in triplicate in at least three   
independent experiments.
Western blot analysis
Cells were lysed in Laemmli buffer and analyzed in a Western blot by 
standard procedures (Rossi et al., 1999). The following primary antibodies   
were used: anti-SF2/ASF mAb96 (Invitrogen), anti-ERK1/2 (EMD), anti–
phospho-ERK1/2 (EMD), anti–phospho-p38 (EMD), anti-p38 (EMD), anti–
-tubulin  (Sigma-Aldrich),  anti-Upf1/RENT1  (Bethyl  Laboratories,  Inc.),   
anti-Myc (Roche), and anti-GFP (Roche). Immunostained bands were de-
tected by the chemiluminescent method (Thermo Fisher Scientific).
Immunoprecipitation
After being washed once with PBS, 2.3 × 10
7 H cells (corresponding to 3 wells 
of a 6-well tissue culture plate) and L cells (corresponding to 6 × 100-mm   
tissue culture dishes) were lysed in 1.5 ml of radio-immunoprecipitation 
assay (RIPA) buffer supplemented with protease inhibitors (complete tablet; 
Roche) and phosphatase inhibitors (PhosSTOP tablet; Roche). The lysate 
was sonicated twice at 50 W for 20 s and centrifuged at 12,000 rpm 
for 10 min at 4°C to remove cell debris. Cell lysates were precleared by 
incubating for 2 h at 4°C with 40 µl of A/G plus–agarose beads (Santa 
Cruz Biotechnology, Inc.). 10 µl of anti-Sam68 (C-20; Santa Cruz Biotech-
nology, Inc.) or anti-IgG (Santa Cruz Biotechnology, Inc.) antibodies were 
conjugated with 40 µl of A/G plus–agarose beads (Santa Cruz Biotechnol-
ogy, Inc.) in RIPA buffer for 1 h at 4°C. Precleared lysates were divided in 
half and incubated overnight at 4°C with anti-Sam68 or with anti-IgG beads. 
during tumor progression, and the production of the oncogenic 
cyclin D1b variant in the human CCND1 gene (Paronetto et al.,   
2010).  Moreover,  Sam68  modulates AS  of  human  BCL-X 
(Paronetto et al., 2007) and murine Sgce (Chawla et al., 2009) gene 
transcripts. Here, we have added the SF2/ASF proto-oncogene 
to the list of Sam68 substrates. Our data indicate that, in ad-
dition to being a direct target of signaling pathways, Sam68 
may transduce the signal to a downstream splicing regulator, 
SF2/ASF, by controlling its mRNA and protein levels through 
AS-NMD. Moreover, similarly to ERK1/2, Sam68 impact on   
EMT/MET  programs  and  its  overexpression  prevents  cell   
density–driven MET in SW480. Because of the relevance of EMT/
MET in the formation of metastases, it is tempting to propose 
a role for Sam68 in cancer progression. In accord with this 
hypothesis, tyrosine phosphorylation of Sam68 is elevated in   
human breast and prostate tumor tissues and cell lines (Paronetto   
et al., 2004; Babic et al.,2004; Lukong et al., 2005). Moreover,   
the expression levels of Sam68 are higher in human prostate   
cancer tissues (Busà et al., 2007; Rajan et al., 2008), and Sam68 
supports prostate cancer cell proliferation and resistance to chemo-
therapeutic agents (Busà et al., 2007). Further indications of a 
role in cell transformation come from studies in mutant mice in 
which Sam68 haplo-insufficiency delays the onset of induced 
breast tumors and decreases the number of metastasis in vivo 
(Richard et al., 2008). Collectively, these data suggest that the 
Sam68 expression level and phosphorylation status play a role 
in tumorigenesis and point to Sam68 as a proto-oncogene. As 
indicated by our analysis, Sam68 could contribute to the malig-
nant transformation of epithelial cancers by up-regulating the 
expression of the proto-oncogene SF2/ASF and inducing a post-
transcriptionally regulated EMT.
Materials and methods
Cell culture, transfection, treatments, and immunofluorescence
Human  colon  carcinoma-derived  SW480  cells  (American  Type  Culture 
Collection, No. CCL-228) were grown in RPMI media supplemented with 
10% FBS, 2 mM l-glutamine, and 25 mM Hepes. To obtain high-density (H) 
and low-density (L) conditions, SW480 cells were plated at 8,000 and 
500 cells/mm
2, respectively. For the transient transfection, we used Lipo-
fectamine 2000 (Invitrogen) as recommended by the provider. After 24 h 
from transfection, H or L cells were plated into 35-mm tissue culture wells 
and analyzed after an additional 24 h. SW480 cells, stably transfected 
with the cDNA of mouse Myc-tagged Sam68 or with the empty vector 
pcDNA3.1 (Invitrogen), were selected in 800 µg/ml G418.
Immunofluorescence was performed on cells fixed in 3% paraformal-
dehyde and stained with antibodies to -catenin (Millipore) or E-cadherin 
(BD)  followed  by  indirect  immunofluorescence  using  TRITC-conjugated 
anti–mouse antibody (Jackson ImmunoResearch Laboratories, Inc.). Nuclei 
were  stained  with  0.1  µg/ml  DAPI  (Sigma-Aldrich).  Slides  were  then 
mounted with MOWIOL reagent (EMD) and analyzed by using an optical 
microscope (IX71; Olympus) equipped with a 60× NA1.25 oil immersion 
objective lens (Olympus; Fig. 1 A). Immunofluorescence images were ac-
quired at room temperature with a digital camera (CoolSNAP; Photometrics) 
and processed using the MetaMorph software (version 6.0/6.1; MDS Ana-
lytical Technologies). Analysis in Fig. 3 D was performed with a digital 
scanning confocal microscope apparatus (TCS-SP2; Leica) equipped with a 
63× NA 1.32 oil immersion objective. We used the 543-nm laser line for 
the TRITC fluorescence (detected at  > 570 nm). Images were exported to 
Photoshop (Adobe). No manipulations were performed other than adjust-
ments in brightness and contrast.
The cell co-culture experiment was performed with tissue culture in-
serts bearing a 0.4-µm pore size polyethylene terephthalate membrane (Corn-
ing). H or L cells were plated into 12-mm tissue culture wells. After 24 h,   JCB • VOLUME 191 • NUMBER 1 • 2010   98
minigenes. Tables S1 and S2 show the sequences of the oligonucleotides used 
for the PCR and qPCR reactions, respectively. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.201001073/DC1.
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After centrifugation, the beads were washed three times with RIPA buffer 
and incubated for 10 min at 95°C with 24 µl of SDS-PAGE protein sample 
buffer. All the immunoprecipitated materials were then analyzed by West-
ern blotting with anti-Sam68 antibody C1-7 (Santa Cruz Biotechnology, 
Inc.) in parallel with a fraction corresponding to 1/10 of the total lysate 
(input). Western blots were analyzed with an antibody directed against 
Phospho-Thr-Pro (Cell Signaling Technology).
In vitro RNA transcription and pull-down assay
100-mer RNA probes containing the first or the second Sam68 binding 
site in the SF2/ASF 3 UTR region or the entire 3 UTR-intron (695 mer)   
were transcribed according to established protocols (Buratti et al., 2004), 
using as templates the minigenes SF2/ASF 3 UTR WT, Mut A+B, and 
Mut A1+B1 and the following set of oligos: T7bsA with bsA, T7bsB with 
bsB, and T7bsA with bsB (Table S1). Sense and antisense oligos carried 
a T7 polymerase promoter sequence and a consensus binding motif for 
TDP-43, respectively. For in vitro pull-down assays, 500 pmol of the tar-
get RNA was placed in a 400-µl reaction mixture containing 100 mM 
NaOAC, pH 5.0, and 5 mM sodium m-periodate (Sigma-Aldrich); incu-
bated for 1 h in the dark at RT; ethanol precipitated; and resuspended   
in 100 µl of 0.1 M NaOAC, pH 5.0. 300 µl of adipic acid dihydra-
zide agarose bead 50% slurry (Sigma) was added, and the mixture was   
equilibrated in 100 mM NaOAC, pH 5.0, then incubated for 12 h at 
4°C on a rotator. The RNA beads were then pelleted, washed three times 
with 1 ml of 2 M NaCl, and equilibrated in washing buffer (5 mM Hepes, 
pH 7.9, 1 mM MgCl2, and 0.8 mM magnesium acetate). They were then 
incubated on a rotator with a protein mixture containing approximately 
1 mg of HeLa cell nuclear extract for 30 min at RT in 1 ml final volume. 
The beads were then pelleted by centrifugation at 3,000 rpm for 3 min 
and washed four times with 1.5 ml of washing buffer before the addition 
of SDS sample buffer and loading on a 10% SDS-PAGE gel. The materi-
als were analyzed by Western blotting with anti-Sam68 antibody C1-7 
(Santa Cruz Biotechnology, Inc.) and with a rabbit polyclonal antibody 
directed against TDP-43 (made in the F.E. Baralle laboratory according 
to standard immunization procedures).
Ribonucleoprotein immunoprecipitation (RIP)
RNA immunoprecipitation was performed as described in Niranjanakumari 
et al. (2002). In brief, 1.8 × 10
7 L cells (corresponding to 2 × 150-mm   
tissue culture dishes) were fixed in 1% formaldehyde for 10 min at RT, 
and then the cross-link reaction was quenched by adding glycine for   
5 min (0.25 M final). Cells were washed with PBS, scraped, collected by 
centrifugation, and resuspended in 10 ml of PBS. 1 ml was saved as input. 
The remaining cells were pelleted and then lysed in 1.5 ml of RIPA buffer, 
sonicated and then centrifuged to remove cell debris. Cell lysates were 
precleared by incubating for 2 h at 4°C with 40 µl of A/G plus–agarose 
beads (Santa Cruz Biotechnology, Inc.). 4 µg of anti-Sam 68 (C-20; Santa 
Cruz Biotechnology, Inc.) or anti-IgG (Santa Cruz Biotechnology, Inc.) was 
conjugated with 40 µl of A/G plus–agarose beads (Santa Cruz Biotech-
nology, Inc.) for 1 h at 4°C. Precleared lysates were divided in half and in-
cubated overnight at 4°C with anti-Sam68 beads or with anti-IgG beads. 
The beads were washed three times with RIPA buffer and the cross-linking 
was reversed by incubating the beads in 40 µl of PBS at 70°C for 45 min. 
RNA was extracted with TRIzol (Invitrogen) according to manufacturer’s 
instructions, and DNase-treated RNA was used in reverse transcriptase 
with random hexamers and Superscript II RT (Invitrogen). Quantitative PCR 
was performed with ASFbsB-for and ASFbsB-rev primers (Table S2).
RNA interference
RNA interference was performed as described previously (Elbashir et al., 
2001). For Upf1, SW480 cells were transfected at 50% confluence with 
Upf1  oligo  (5-TTCCACTGCTAAAACTGAA-3)  using  Oligofectamine   
(Invitrogen). After 24 h, cells were seeded at high density into 35-mm tissue 
culture wells and assayed after an additional 24 h. For Sam68, 5 × 10
5 
SW480 cells were transfected three times at 24 h intervals with Sam68-1 
oligo (Cheng and Sharp, 2006) and assayed 24 h after the third trans-
fection. As a control in all experiments, cells were transfected with GL2- 
luciferase oligo (Elbashir et al., 2001).
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